Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49,578
Next Earnings Date5/12/2020 (Estimated)
OptionableOptionable
Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions
What is Takeda Pharmaceutical's stock symbol?
Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."
How were Takeda Pharmaceutical's earnings last quarter?
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced its quarterly earnings results on Tuesday, February, 4th. The company reported $0.53 earnings per share for the quarter. The firm had revenue of $7.90 billion for the quarter. View Takeda Pharmaceutical's Earnings History.
When is Takeda Pharmaceutical's next earnings date?
What guidance has Takeda Pharmaceutical issued on next quarter's earnings?
Takeda Pharmaceutical issued an update on its FY 2019
Pre-Market earnings guidance on Tuesday, February, 4th. The company provided earnings per share guidance of 3.53-3.72 for the period. The company issued revenue guidance of $30.147-30.147 billion.
What price target have analysts set for TAK?
4 Wall Street analysts have issued twelve-month price targets for Takeda Pharmaceutical's shares. Their forecasts range from $19.50 to $19.50. On average, they anticipate Takeda Pharmaceutical's share price to reach $19.50 in the next year. This suggests a possible upside of 0.3% from the stock's current price. View Analyst Price Targets for Takeda Pharmaceutical.
What is the consensus analysts' recommendation for Takeda Pharmaceutical?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Takeda Pharmaceutical.
Has Takeda Pharmaceutical been receiving favorable news coverage?
News articles about TAK stock have trended somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Takeda Pharmaceutical earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Takeda Pharmaceutical.
What other stocks do shareholders of Takeda Pharmaceutical own?
Who are Takeda Pharmaceutical's key executives?
Takeda Pharmaceutical's management team includes the folowing people:
- Mr. Christophe Weber, Pres, CEO & Representative Director (Age 53)
- Dr. Andrew S. Plump, Chief Medical & Scientific Officer and Director (Age 54)
- Dr. Seigo Izumo M.D., Chair of Management Board
- Mr. Costa Saroukos, Chief Financial Officer (Age 48)
- Mr. Haruhiko Hirate, Member of Management Board & Corp. Communications and Public Affairs Officer (Age 62)
Who are Takeda Pharmaceutical's major shareholders?
Takeda Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional investors include Adelphi Capital LLP (0.29%), Bank of America Corp DE (0.13%), First Trust Advisors LP (0.07%), Renaissance Technologies LLC (0.06%), Goldman Sachs Group Inc. (0.06%) and Brandes Investment Partners LP (0.05%).
Which major investors are selling Takeda Pharmaceutical stock?
TAK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, UBS Asset Management Americas Inc., TIG Advisors LLC, Franklin Resources Inc., Marshall Wace North America L.P., Brandes Investment Partners LP, Jane Street Group LLC and Bank of America Corp DE.
Which major investors are buying Takeda Pharmaceutical stock?
TAK stock was bought by a variety of institutional investors in the last quarter, including Ovata Capital Management Ltd, Renaissance Technologies LLC, Raymond James & Associates, TD Asset Management Inc., Blueshift Asset Management LLC, Van ECK Associates Corp, Eagle Global Advisors LLC and Magnetar Financial LLC.
How do I buy shares of Takeda Pharmaceutical?
Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Takeda Pharmaceutical's stock price today?
One share of TAK stock can currently be purchased for approximately $19.44.
MarketBeat Community Rating for Takeda Pharmaceutical (NYSE TAK)
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TAK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TAK will underperform the S&P 500 over the long term. You may vote once every thirty days.
